|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma.
|
28701723 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
According to cancer-genome sequences, > 90% of cases of pancreatic ductal adenocarcinoma (PDAC) harbor active KRAS mutations.
|
31746520 |
2020 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In mice, a high-fat diet (HFD) and expression of oncogenic KRAS lead to development of invasive pancreatic ductal adenocarcinoma (PDAC) by unknown mechanisms.
|
31352001 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations in the KRAS oncogene are prevalent in pancreatic ductal adenocarcinoma (PDAC).
|
25250570 |
2014 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic ductal adenocarcinoma (PDA) is characterized by an activating mutation in KRAS.
|
30938713 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.
|
20814421 |
2010 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Development of pancreatic ductal adenocarcinoma (PDAC) involves activation of c-Ki-ras2 Kirsten rat sarcoma oncogene homolog (KRAS) signaling, but little is known about the roles of proteins that regulate the activity of oncogenic KRAS.
|
24998203 |
2014 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma.
|
31492820 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.
|
24803537 |
2014 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation status seems to identify two different subtypes of pancreatic ductal adenocarcinoma with similar outcome but distinct molecular features and probably different therapeutic targets.
|
26161927 |
2015 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The KRAS mutation is the driving force of pancreatic ductal adenocarcinoma (PDAC).
|
30041673 |
2018 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In pancreatic ductal adenocarcinoma (PDAC), mutant KRAS stimulates the translation initiation factor eIF5A and upregulates the focal adhesion kinase PEAK1, which transmits integrin and growth factor signals mediated by the tumor microenvironment.
|
28381547 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Deltarasin is a recently identified small molecule that can inhibit KRAS-PDEδ interactions by binding to a hydrophobic pocket on PDEδ, resulting in the impairment of cell growth, KRAS activity, and RAS/RAF signaling in human pancreatic ductal adenocarcinoma cell lines.
|
29440631 |
2018 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
|
21894049 |
2011 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, this raises the possibility that the farnesylated but nonpalmitoylated state 1, like K-Ras4B, binds calmodulin and is associated with colorectal and other adenocarcinomas like lung cancer and pancreatic ductal adenocarcinoma.
|
26659836 |
2016 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the context of pancreatic ductal adenocarcinoma (PDAC), oncogenic KRAS induces benign pancreatic intraepithelial neoplasias (PanINs), which exhibit features of oncogene-induced senescence.
|
30614183 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinically, KRAS mutation is sometimes requested on cytology/biopsy specimens and negative results are helpful to rule out pancreatic ductal adenocarcinoma.
|
26474433 |
2016 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
|
29024530 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma.
|
27974679 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA) but remains an intractable pharmacologic target.
|
22628411 |
2012 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma.
|
30747828 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and epidermal growth factor receptor (EGFR) family signaling are drivers of tumorigenesis in pancreatic ductal adenocarcinoma (PDAC).
|
25117978 |
2014 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One of the major genetic alterations in pancreatic ductal adenocarcinoma (PDAC) is the point mutation of K-ras gene.
|
28969083 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obesity driven by chronic consumption of high-fat diet (HFD) is a major risk factor for oncogenic KRAS-mediated pancreatic ductal adenocarcinoma (PDAC).
|
30819189 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The initiation of pancreatic ductal adenocarcinoma (PDA) is linked to activating mutations in KRAS.
|
25593307 |
2015 |